News

In metastatic triple-negative breast cancer, sacituzumab govitecan was effective and tolerable in the real-world setting.

Scott Eggener, MD, gave a talk at the LUGPA annual meeting titled “Leveraging Cutting-Edge Technologies to Enhance Prostate Cancer Treatments.”

Ken Kato, MD, PhD, and Harry H. Yoon, MD, MHS, discussed the recent FDA approval of tislelizumab in the first line for patients with esophageal squamous cell carcinoma.

Anthony Stein, MD, assessed total marrow and lymphoid irradiation with post-transplant cyclophosphamide in patients with acute myeloid leukemia.

177Lu rhPSMA-10.1 showed high tumor radiation with low healthy tissue exposure in a phase 1/2 trial for metastatic castration-resistant prostate cancer.

Elacestrant prolonged progression-free survival in patients with pretreated, ER-positive, HER2-negative breast cancer.

In this episode of Targeted Talks, Alfred L. Garfall, discusses the phase 2 BMT CTN 1902 trial of idecabtagene vicleucel in patients with multiple myeloma.

A phase 1 trial is evaluating Actimab-A, venetoclax, and ASTX-727 in frontline acute myeloid leukemia, with initial data expected later this year.

A real-world study showed HER2DX guided treatment changes in approximately 48% of HER2-positive breast cancer cases.

The TEDOPaM trial evaluating a novel maintenance therapy approach for advanced/metastatic pancreatic ductal adenocarcinoma has met its primary end point.

An expanded access program evaluating cretostimogene grenadenorepvec was highlighted during the 25th Annual Meeting of the Society of Urologic Oncology.

Jason M. Hafron, MD, CMO, discusses recent approvals in the non–muscle-invasive bladder cancer space and data from several clinical trials evaluating agents for bladder cancer.

Geoffrey Shouse, DO, PhD, discusses the growing interest in bispecific antibodies within the field of oncology.

Julie Gralow, MD, shed light on the factors contributing to the growing shortage of oncologists in the US and what can be done to address it.

Novel HER2 therapies show strong intracranial efficacy, enabling systemic treatment over local therapy for small, asymptomatic brain metastases in metastatic breast cancer.

BCG with gemcitabine was linked to strong early oncological efficacy and safety in previously treated patients with non–muscle-invasive bladder cancer.

New agents targeting endocrine therapy and CDK4/6 resistance in hormone receptor–positive breast cancer are in development.

Jennifer Marie Suga, MD, shares the lung cancer research she’s eager to explore as new data emerges.

Matthew Matasar, MD, discussed what the findings from the ELM-1 trial of odronextamab in diffuse large B-cell lymphoma mean for oncologists.

The first patient was dosed in a phase 1/2 trial of evofosfamide with checkpoint inhibitors for hypoxia-reversal in resistant solid tumors.

Treatment of unresponsive non–muscle-invasive bladder cancer with nadofaragene firadenovec showed a 66% chance of survival and cystectomy-free status at 60 months.

Forward steps are being made in HNSCC, and the first patient with MDS has been treated with iadademstat/azacitidine.

Marwan G. Fakih, MD, discusses the next steps for the clinical development of the balstilimab plus botensilimab in microsatellite stable metastatic colorectal cancer without liver metastases.

Paolo Ghia, MD, PhD, discusses the CAPTIVATE trial in chronic lymphocytic leukemia/small lymphocytic lymphoma, and what findings from the trial have been particularly noteworthy.

Immunotherapy advances in triple-negative breast cancer drive personalized treatments with immune checkpoint inhibitors, aiding subtype identification and new combination therapy developments.

The FDA cleared the investigational new drug application for MRANK-106, a dual WEE1/YES1 kinase inhibitor, targeting advanced solid tumors.

Hedy Lee Kindler, MD, explains the new treatment updates for patients with mesothelioma.

For Colorectal Cancer Awareness Month, Scott Kopetz, MD, PhD, FACP, discussed the BREAKWATER trial in metastatic BRAF V600E-mutated colorectal cancer.

The FDA granted orphan drug status to rhenium-186 obisbemeda for treating leptomeningeal metastases in lung cancer.

MATTERHORN is the first global phase 3 trial to show improved event-free survival with an immunotherapy combo vs standard care in this patient population.